Novartis to support Pfizer-BioNTechs Covid-19 vaccine production

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Novartis has signed an initial agreement to support the production of Pfizer and BioNTech’s Covid-19 vaccine by leveraging its manufacturing capacity and capabilities to fight the Covid-19 pandemic.

Novartis has signed an initial agreement to support the production of Pfizer and BioNTech’s Covid-19 vaccine by leveraging its manufacturing capacity and capabilities to fight the Covid-19 pandemic.

The company will use its aseptic manufacturing facilities at its site in Stein, Switzerland for the purpose.

According to the agreement, Novartis intends to obtain bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions.

It will be sent for shipment to BioNTech for delivery to healthcare system customers across the globe.

On reaching a final agreement, Novartis intends to initiate production in the second quarter of this year at its plant in Stein with the delivery of initial shipment expected in the third quarter.

Furthermore, the Novartis manufacturing team is in advanced talks with various additional companies to take on manufacturing processes like mRNA production, therapeutic protein production and producing raw material needed for Covid-19 vaccines and therapeutics.

Novartis Technical Operations Head Steffen Lang said: “Novartis has been mobilising on multiple fronts to support the global pandemic response.

“As a company reimagining medicine with advanced therapy platforms, we are committed to leverage our manufacturing capabilities to help support the supply of Covid-19 vaccines and therapeutics around the world.”

So far, the Pfizer-BioNTech Covid-19 vaccine is authorised for use by the health regulatory authorities of approximately 50 countries.

The vaccine received conditional marketing authorisation in Switzerland and the European Union member states while granted emergency use authorisation in the UK, the US and Canada and Hong Kong.

 

Latest stories

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back